Estimating the Effect of Coronavirus Disease 2019 (COVID-19) Vaccination and Infection Variant on Post-COVID-19 Venous Thrombosis or Embolism Risk

Andrew O'Carroll,Stephanie A Richard,Celia Byrne,Jennifer Rusiecki,Ben Wier,Catherine M Berjohn,Anthony C Fries,Tahaniyat Lalani,Alfred G Smith,Rupal M Mody,Anuradha Ganesan,Nikhil Huprikar,Rhonda E Colombo,Christina Schofield,David A Lindholm,Katrin Mende,Milissa U Jones,Ryan Flanagan,Derek T Larson,Evan C Ewers,David Saunders,Ryan C Maves,Carlos J Maldonado,Margaret Sanchez Edwards,Robert J O'Connell,Mark P Simons,David R Tribble,Brian K Agan,Timothy H Burgess,Simon D Pollett

DOI: https://doi.org/10.1093/ofid/ofae557

2024-09-23

Abstract:Background: Previous research has shown that vaccination reduces risk of post-coronavirus disease 2019 (COVID-19) venous thrombosis or embolism (VTE), but the effect of vaccine boosting on post-COVID-19 VTE risk reduction is unclear. We sought to estimate the effect of COVID-19 vaccination on the risk of post-COVID-19 VTE and to examine if the magnitude of this association differed among variant eras. Methods: We performed a case-control study of Military Health System (MHS) beneficiaries who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2020-2022. Cases were defined as those with medically attended VTE within 90 days after their first positive SARS-CoV-2 test; controls were defined as SARS-CoV-2 infections without incident VTE by 90 days. Multivariate logistic regression estimated the odds of post-SARS-CoV-2 VTE based on pre-COVID-19 vaccine status, adjusting for other VTE risk factors. Results: A total of 4646 MHS beneficiaries were included in this analysis; 1370 received a primary vaccine series and a further 790 received at least 1 booster at time of infection; 71 had VTE within 90 days of SARS-CoV-2 infection. Those who were vaccinated had lower odds of VTE (adjusted odds ratio [95% confidence interval]) compared to the unvaccinated following infection (primary series: 0.28 [.13-.62]; booster dose: 0.06 [.01-.46]). Post-COVID-19 VTE risk was lowest during the Omicron era, but VTEs were too rare to examine for an interaction of variant era and vaccine effect. Conclusions: Among MHS beneficiaries, COVID-19 vaccination was associated with a reduced risk of post-COVID-19 VTE diagnosis; estimated risk reduction was larger among those who received a booster.